复方桑白皮方对2型糖尿病小鼠糖代谢、炎症及氧化应激的改善作用及机制*

作者：沈扬帆1,2，李艺含2，李壮壮2，胡佳裕2，刘征堂2

单位：1.北京中医药大学研究生院，北京 100029；2.中国中医科学院西苑医院，北京 100091

引用：引用：沈扬帆，李艺含，李壮壮，胡佳裕，刘征堂.复方桑白皮方对2型糖尿病小鼠糖代谢、炎症及氧化应激的改善作用及机制[J].中医药导报,2025,31(5):1-7.

DOI：10.13862/j.cn43-1446/r.2025.05.001

PDF： 下载PDF

摘要：

目的：探究复方桑白皮方对2型糖尿病（T2DM）小鼠糖代谢、炎症及氧化应激的干预作用及机制。方法：取90只SPF级雄性健康C57BL/6小鼠，随机分为空白组（n=10）和造模组（n=80）。造模组采用高糖高脂喂养联合链脲佐菌素（STZ，50 mg/kg）注射建立T2DM模型，造模成功后随机分为模型组、二甲双胍组、复方桑白皮方低剂量组、复方桑白皮方中剂量组、复方桑白皮方高剂量组，每组10只，干预5周。干预期间检测小鼠空腹血糖，并进行葡萄糖耐量试验（OGTT）、胰岛素耐量试验（ITT），5周后检测外周血中糖代谢指标[糖化血红蛋白（GHb）、糖化血清蛋白（GSP）、胰高血糖素样肽-1（GLP-1）、胰岛素（INS）]、抗氧化指标[超氧化物歧化酶（SOD）、丙二醛（MDA）、谷胱甘肽过氧化物酶（GSH-Px）、过氧化氢酶（CAT）]及炎症因子[白介素-6（IL-6）、白介素-1β（IL-1β）、肿瘤坏死因子-α（TNF-α）]水平。结果：与模型组比较，复方桑白皮方低、中、高剂量组小鼠空腹血糖均下降（P<0.05），复方桑白皮方中、高剂量组小鼠GHb及GSP均降低（P<0.05），复方桑白皮方高剂量组INS及复方桑白皮方中、高剂量组GLP-1均升高（P<0.05）；OGTT及ITT试验复方桑白皮方中、高剂量组小鼠在60、90、120 min时与模型组比较，差异均有统计学意义（P＜0.05），曲线下面积显著减小（P＜0.05）；氧化应激方面，复方桑白皮方中、高剂量组小鼠CAT、SOD、GSH-Px水平高于模型组（P<0.05），MDA水平低于模型组（P<0.05）；炎症因子方面，复方桑白皮方中、高剂量组小鼠治疗后IL-6、IL-1β、TNF-α水平低于模型组（P<0.05）。结论：复方桑白皮方可降低T2DM小鼠血糖水平，改善小鼠糖代谢功能，其机制可能与增强机体抗氧化、抗炎能力有关。

关键词：2型糖尿病；复方桑白皮方；药效学；糖代谢；氧化应激；炎症反应；小鼠

Abstract：

Objective: To investigate the intervention effects of the compound Sangbaipi formula on glucose metabolism, inflammatory factors and oxidative stress in type 2 diabetes (T2DM) mice. Methods: Totally 90 SPF-grade male C57BL/6 mice were randomly divided into blank group (n=10) and modelling group (n=80). The T2DM model was established by feeding high-fat, high-sugar diet combined with a single injection of streptozotocin (STZ, 50 mg/kg). After successful modeling, the mice were randomly divided into model group, metformin group, low-dose compound Sangbaipi formula group (low-dose group), medium-dose compound Sangbaipi formula group (medium-dose group), and high-dose compound Sangbaipi formula group (high-dose group), with 10 mice in each group. The intervention lasted for 5 weeks. During the intervention, fasting blood glucose level was monitored, and oral glucose tolerance test (OGTT) and insulin tolerance test (ITT) were performed. After 5 weeks, glucose metabolism (GHb, GSP, GLP-1, INS), antioxidant markers (SOD, MDA, GSH-Px, CAT), and inflammatory factors (IL-6, IL-1β, TNF-α) were measured in peripheral blood. Results: Compared to the model group, fasting blood glucose levels decreased in low-dose group, medium-dose group and high-dose group (P<0.05). The medium-dose group and high-dose group showed reductions in GHb and GSP levels (P<0.05). INS levels in the high-dose group and GLP-1 levels in the medium and high-dose groups increased (P<0.05). In the OGTT and ITT tests, significant differences were observed at 60, 90, and 120 minutes between the medium-dose group and high-dose group and the model group (P<0.05), and the area under the curve significantly decreased (P<0.05). In terms of oxidative stress, the medium-dose group and high-dose group showed higher levels of CAT, SOD, and GSH-Px than model group (P<0.05), while lower levels of MDA than model group (P<0.05). In inflammatory factors, the medium-dose group and high-dose group showed lower levels of IL-6, IL-1β, and TNF-α than model group (P<0.05). Conclusion: The compound Sangbaipi formula can lower blood glucose levels in T2DM mice and improve glucose metabolism. The underlying mechanisms may involve enhancing antioxidant and anti-inflammatory responses in the body.

Key words：type 2 diabetes; compound Sangbaipi formula; pharmacodynamics; glucose metabolism; oxidative stress; inflammatory response; mice

发布时间：2025-12-23

点击量：97